Large-scale pancreatic cancer detection via non-contrast CT and deep learning.
Kai Cao, Yingda Xia, Jiawen Yao...
https://pubmed.ncbi.nlm.nih.gov/37985692Actively Recruiting
Age: 50Years +
All Genders
Healthy Volunteers
ID07117045
Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer
Led by Changhai Hospital · Updated on 2025-08-12
400000
Participants Needed
5
Research Sites
104 weeks
Total Duration
On this page
Sponsors
C
Changhai Hospital
Lead Sponsor
T
The Affiliated People's Hospital of Ningbo University
Collaborating Sponsor
AI-Summary
What this Trial Is About
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with a low 5-year survival rate, making early diagnosis vital to improving outcomes. Current screening methods are limited and often miss early-stage disease, especially for the general public. Researchers are evaluating the use of an Artificial Intelligence (AI) system called PANDA combined with low-dose computed tomography (LDCT) to enhance pancreatic cancer screening in a prospective, multicenter, observational cohort, aiming to improve early detection and reduce unnecessary procedures. Participants will undergo annual LDCT scans analyzed by the PANDA AI system. Abnormal findings identified by the AI are reviewed by a multidisciplinary team (MDT) to decide next steps: suspected pancreatic cancer or precursor lesions lead to hospital examinations; benign lesions receive personalized monitoring; and cases confirmed as normal by MDT will have at least one year of follow-up. If abnormalities appear during follow-up, participants will be managed accordingly. This approach focuses on evaluating detection rates, predictive values, consensus, and recall rates over two years. During the study, participants will complete LDCT exams and consent to follow-up assessments based on AI and MDT findings. Researchers will monitor pancreatic cancer detection rates, early-stage cancer proportions, and safety indicators like false positives and unnecessary invasive procedures. Follow-up will continue for at least one year for some participants, with ongoing monitoring to assess the effectiveness and safety of AI-assisted LDCT screening in a health check-up population.
CONDITIONS
Brief Title
Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer
Who Can Participate
Age: 50Years +
All Genders
Healthy Volunteers
Eligibility Criteria
You may qualify if you...
- Age 50 years and above
- Voluntary signing of informed consent
- Completion of low-dose computed tomography (LDCT) examination
You will not qualify if you...
- Previous history of pancreatic cancer
- Abdominal inflammation or diagnosis of acute pancreatitis within 6 months
- Poor image quality due to ascites, pancreatic trauma, thoracic/abdominal surgery, radiotherapy, or chemotherapy
- Unable to complete follow-up due to physical or other reasons
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Surveillance
Duration - Up to 2 years
Participants undergo annual screening with the low-dose CT combined with AI system to detect pancreatic abnormalities.
Annual visits for screening
Diagnostic Evaluation
Duration - Varies depending on findings
For participants with positive AI findings, a multidisciplinary team reviews results to determine further steps including hospital examination or personalized monitoring.
1 to multiple visits depending on diagnostic needs
Long-term Monitoring
Duration - At least 1 year
Participants with benign lesions or confirmed normal pancreatic issues receive personalized monitoring for at least one year, with management adjusted if abnormalities arise.
Periodic visits based on monitoring plan
Trial Site Locations
Total: 5 locations
1
Meinian Onehealth Healthcare Holdings Co., Ltd
Shanghai, Shanghai Municipality, China, 200072
Actively Recruiting
2
Ruici Medical Examination Institution
Shanghai, Shanghai Municipality, China, 200126
Actively Recruiting
3
Changhai Hospital
Shanghai, Shanghai Municipality, China, 200433
Actively Recruiting
4
Jiaxing University Affiliated Second Hospital
Jiaxing, Zhejiang, China, 314000
Actively Recruiting
5
Ningbo University Affiliated People's Hospital
Ningbo, Zhejiang, China, 315100
Actively Recruiting
Loading map...
Research Team
W
Wang Bei Lei, M.D.
G
Guo Shi Wei, M.D.
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Pancreatic cancer.
Jonathan D Mizrahi, Rishi Surana, Juan W Valle...
https://pubmed.ncbi.nlm.nih.gov/32593337Early detection of pancreatic cancer.
Stephen P Pereira, Lucy Oldfield, Alexander Ney...
https://pubmed.ncbi.nlm.nih.gov/32135127Survival Prediction in Pancreatic Ductal Adenocarcinoma by Quantitative Computed Tomography Image Analysis.
Marc A Attiyeh, Jayasree Chakraborty, Alexandre Doussot...
https://pubmed.ncbi.nlm.nih.gov/29380093End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed tomography.
Diego Ardila, Atilla P Kiraly, Sujeeth Bharadwaj...
https://pubmed.ncbi.nlm.nih.gov/31110349Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment.
Laura D Wood, Marcia Irene Canto, Elizabeth M Jaffee...
https://pubmed.ncbi.nlm.nih.gov/35398344Early Detection of Pancreatic Cancer: Opportunities and Challenges.
Aatur D Singhi, Eugene J Koay, Suresh T Chari...
https://pubmed.ncbi.nlm.nih.gov/30721664Application of Deep Learning to Pancreatic Cancer Detection: Lessons Learned From Our Initial Experience.
Linda C Chu, Seyoun Park, Satomi Kawamoto...
https://pubmed.ncbi.nlm.nih.gov/31492412GI cancer mortality in participants in low dose CT screening for lung cancer with a focus on pancreatic cancer.
Louis Gros, Rowena Yip, Yeqing Zhu...
https://pubmed.ncbi.nlm.nih.gov/39617764